产后布普伦诺芬:对剂量调整和治疗保留的描述性分析
Journal of addiction medicine
|March 17, 2026
概括
大多数产后患者维持或增加了布普伦诺芬剂量,剂量减少很少. 个性化布普伦诺芬管理对于阿片类药物使用障碍的治疗保留至关重要.
科学领域:
- 产科和妇科 产科和妇科
- 成 药物 药物 药物 药物
- 药理学 药理学是指药理学的学科.
背景情况:
- 布普伦诺芬是阿片类药物使用障碍 (OUD) 的关键治疗方法.
- 产前期的生理和心理社会变化需要调整布普伦诺芬剂量.
- 了解产后布普伦诺芬剂量对于母亲和婴儿的健康至关重要.
研究的目的:
- 描述产后布普伦诺芬剂量变化.
- 分析剂量调整中的人口变化.
- 评估剂量变化与治疗持续时间之间的关联.
主要方法:
- 对66名患者进行了回顾性描述性分析.
- 检查了从分娩到产后3个月的布普伦诺芬剂量变化.
- 在产后1年评估治疗持续时间.
主要成果:
- 55%没有改变剂量;33%增加剂量;12%降低产后剂量.
- 被监禁的人更有可能减少剂量 (P=0.045).
- 两组之间1年治疗持续时间没有显著差异.
结论:
- 产后布普伦诺芬管理显示异质性.
- 88%的患者维持或增加了剂量.
- 考虑剂量,生物心理社会因素和过量剂量风险的个性化护理是必不可少的.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Excretion
360
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
360
Oral Drug Delivery Systems: Continuous-Release Systems
162
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
162
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
846
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
846
Renal Failure: Dose Adjustments
566
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
566
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
296
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
296
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
327
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
327


